Zobrazeno 1 - 10
of 41
pro vyhledávání: '"J. G. Mills"'
Autor:
U, Reininghaus, C, Gayer-Anderson, L, Valmaggia, M J, Kempton, M, Calem, A, Onyejiaka, K, Hubbard, P, Dazzan, S, Beards, H L, Fisher, J G, Mills, P, McGuire, T K J, Craig, P, Garety, J, van Os, R M, Murray, T, Wykes, I, Myin-Germeys, C, Morgan
Publikováno v:
Psychological Medicine
Background Evidence has accumulated that implicates childhood trauma in the aetiology of psychosis, but our understanding of the putative psychological processes and mechanisms through which childhood trauma impacts on individuals and contributes to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee18a90333a1117ae49875abca2725d7
https://pubmed.ncbi.nlm.nih.gov/27400863
https://pubmed.ncbi.nlm.nih.gov/27400863
Publikováno v:
Alimentary Pharmacology & Therapeutics. 3:353-365
The literature was searched for clinical trials evaluating the use of 300 mg ranitidine daily in the acute treatment of gastric ulcer. All available trials were examined, and the results compared between countries to determine the extent of any geogr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3377cca1ea4eb5757aad1d2e033b76c5
https://doi.org/10.1111/j.1365-2036.1989.tb00222.x
https://doi.org/10.1111/j.1365-2036.1989.tb00222.x
Publikováno v:
Alimentary Pharmacology & Therapeutics. 14:23-34
Background: Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism at the 5-HT3 receptor may be of benefit in the treatment of irritable bowel syndrome. Aims:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4d3a4229f8ce56d7d8e31d1e658013b
https://doi.org/10.1046/j.1365-2036.2000.00684.x
https://doi.org/10.1046/j.1365-2036.2000.00684.x
Autor:
R. S. B. Ehsanullah, J. G. Mills, R. H. Jones, Gerald Holtmann, L. A. Jacques, Luis Rodrigo, P. M. Crompton
Publikováno v:
Alimentary Pharmacology & Therapeutics. 13:1419-1427
Background : Irritable bowel syndrome is one of the most common gastrointestinal disorders, yet no therapy convincingly controls the multiple symptoms of this syndrome. Aim : To compare the efficacy and tolerability of the new 5-HT3-receptor antagoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90d0df2e9cacf62c9cb9aef461a023f4
https://doi.org/10.1046/j.1365-2036.1999.00678.x
https://doi.org/10.1046/j.1365-2036.1999.00678.x
Autor:
G. A. Pipkin, J. G. Mills
Publikováno v:
Scandinavian Journal of Gastroenterology. 34:3-8
Background : The majority of patients who have symptomatic acid reflux disease will have a normal oesophageal mucosa or will have only a mild degree of oesophagitis. Treatment to relieve symptoms as they occur may be the best way to manage these pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e9d626c03afcd856ce60bd1b07cc85
https://doi.org/10.1080/003655299750025471
https://doi.org/10.1080/003655299750025471
Publikováno v:
Digestive Diseases and Sciences. 38:1459-1467
A double-blind multinational comparison of ranitidine 300 mg post evening meal (pem), ranitidine 300 mg nocte and cimetidine 800 mg nocte has been carried out in 1677 patients with endoscopically verified duodenal ulcer disease. Fifty-three percent o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f14d59a6135f2414694bf1f49f3a4a6
https://doi.org/10.1007/bf01308604
https://doi.org/10.1007/bf01308604
Publikováno v:
Age and Ageing. 22:411-418
This multinational double-blind trial compared the efficacy and safety of ranitidine 300 mg nocte, 300 mg post-evening meal (pem) and cimetidine 800 mg nocte in patients with endoscopically verified duodenal ulcer disease aged60 years (n = 1318) ando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd732d3ad8768669e1789e52566dc41
https://doi.org/10.1093/ageing/22.6.411
https://doi.org/10.1093/ageing/22.6.411
Publikováno v:
ChemInform. 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f72f969d4a5457dcebb9048de80eb84f
https://doi.org/10.1002/chin.199348076
https://doi.org/10.1002/chin.199348076
Publikováno v:
Alimentary pharmacologytherapeutics. 14(1)
Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism at the 5-HT3 receptor may be of benefit in the treatment of irritable bowel syndrome.To evaluate the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b2f73d5fa6ea5b7d8157d3851ec1cfc
https://pubmed.ncbi.nlm.nih.gov/10632642
https://pubmed.ncbi.nlm.nih.gov/10632642
Autor:
R H, Jones, G, Holtmann, L, Rodrigo, R S, Ehsanullah, P M, Crompton, L A, Jacques, J G, Mills
Publikováno v:
Alimentary pharmacologytherapeutics. 13(11)
Irritable bowel syndrome is one of the most common gastrointestinal disorders, yet no therapy convincingly controls the multiple symptoms of this syndrome.To compare the efficacy and tolerability of the new 5-HT3-receptor antagonist alosetron and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::852e906e531341481096239920a6a31f
https://pubmed.ncbi.nlm.nih.gov/10571597
https://pubmed.ncbi.nlm.nih.gov/10571597